This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
News|Articles|January 6, 2026
Q4 2025 Recap: Dermatology News and Updates
Author(s)Tim Smith
Fact checked by: Abigail Brooks, MA
This quarterly recap highlights some of the most notable news and developments in the dermatology space from Q4 in 2025.
Advertisement
Advertisement
The fourth quarter of 2025 saw several notable developments in the field of
Related to this article
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.
Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.
In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.
Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.
The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.
Advertisement
Advertisement